While there are benefits of gene therapy, some patients will continue to need anti–vascular endothelial growth factor (VEGF) therapy to treat wet age-related macular degeneration (AMD), said Charles C. Wykoff, MD, PhD, of Retina Consultants of Texas and the Blanton Eye Institute at Houston Methodist Hospital.
While there are benefits of gene therapy, some patients will continue to need anti–vascular endothelial growth factor (VEGF) therapy to treat wet age-related macular degeneration, said Charles C. Wykoff, MD, PhD, director of research at Retina Consultants of Texas; chair of research, Retina Consultants of America; and deputy chair of ophthalmology for the Blanton Eye Institute, Houston Methodist Hospital.
Transcript
What are the benefits in outcomes of using gene therapy over anti-VEGF injections in wet age-related macular degeneration?
We've had anti-VEGF injections now for over 15 years. And thank goodness we've had them. We've been able to really change the epidemiology of blindness around the world because of them. I don't see a gene therapy like this replacing the need for intravitreal injections. I mean, this gene therapy is only being utilized in these trials among patients who are previously treated. It's really important to demonstrate responsiveness before you give someone a potentially one-and-done therapy, like a gene therapy. You want to make sure that they're anti-VEGF responsive. And then certainly some patients will be good candidates for gene therapy, and others may not.
I think that a gene therapy like this is going to be very clinically useful and valuable for many patients. But some patients will continue to receive anti-VEGF bolus injection monotherapy. Even among the patients that can get gene therapy, we're seeing that a that a that a minority of patients, but a meaningful minority—27% to 40% of eyes—are receiving ongoing anti-VEGF injections after the gene therapy treatment. The hope is that many patients will not need ongoing therapy, repeated bolus injections, but some patients will. It's going to be sort of a hybrid model depending on each patient's responsiveness to the gene therapy when this is available commercially.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More